PicoCELA Inc. (NASDAQ:PCLA) Sees Large Drop in Short Interest

PicoCELA Inc. (NASDAQ:PCLA) saw a large decline in short interest in the month of January. As of January 15th, there was short interest totaling 1,932,063 shares, a decline of 46.7% from the December 31st total of 3,625,291 shares. Based on an average trading volume of 4,234,824 shares, the short-interest ratio is presently 0.5 days. Approximately 212.3% of the company’s stock are sold short. Approximately 212.3% of the company’s stock are sold short. Based on an average trading volume of 4,234,824 shares, the short-interest ratio is presently 0.5 days.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of PicoCELA in a report on Friday, January 9th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in PicoCELA stock. XTX Topco Ltd bought a new position in PicoCELA Inc. (NASDAQ:PCLA) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 44,648 shares of the company’s stock, valued at approximately $72,000. XTX Topco Ltd owned about 0.16% of PicoCELA at the end of the most recent reporting period.

PicoCELA Price Performance

Shares of NASDAQ:PCLA traded up $0.56 during trading on Friday, reaching $6.33. 45,830 shares of the stock were exchanged, compared to its average volume of 103,227. PicoCELA has a 1-year low of $3.46 and a 1-year high of $294.00. The stock has a fifty day moving average of $7.59 and a two-hundred day moving average of $11.67.

About PicoCELA

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.